Connect with the future of healthcare
Prematurely-born infants are at high risk of life-long brain damage, caused by harmful oxygen levels in the brain. As this is invisible from the outside, we offer next-generation sensors to help clinicians react before damage occurs.
Alongside professional investors, you can now invest in OxyPrem, to improve medical care for the most fragile patients.
In the market
17.110.409€
2025-2026
Medical devices
12%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
«Our ultimate vision is that, no matter whether you are in a developed or a less-developed country, too early-born children can have our brain monitoring solutions, helping to prevent severe life-long consequences.»
10% of all children are born too early. They are one of the most vulnerable patient groups and require extra careful handling and treatment. Due to their underdeveloped organs, prematurely-born children struggle with the early steps into life. Especially the brain has difficulties to regulate oxygen levels.
If the brain cannot regulate oxygen levels properly, both too little and too much oxygen is harmful: If there is not enough oxygen, brain cells die (leading to death and disabilities). If there is too much oxygen, there is a serious risk of blindness.
Inadequate brain oxygen levels are invisible to the human eye, creating considerable insecurity to medical teams and parents. And to make matters worse: Just 5 minutes of inadequate oxygen are enough to cause permanent brain damage. 46% of survivors of severe prematurity suffer from life-long disabilities, such as cerebral palsy, inability to walk, paralyses, missing hearing and vision, low IQ, and others.
Following an urgent request by the clinical field, the OxyPrem team has created a next-generation preterm-specific, high-precision, reusable technology to monitor brain oxygen levels. In 2020, we introduced a first limited series of CE marked devices to the market, which has been used by 38 hospitals across 12 countries until today.
We are now working on the release of OxyPrem NOAH, our second generation of brain oxygen sensors, expected to be available in early 2025. We are currently setting up full commercialization of this product, also working with strategic partners and specialized distributors. In parallel, we are actively engaging in conversations with potential acquisition partners.
With the crowdinvesting campaign presented to you today, you have the opportunity to become an OxyPrem investor, alongside professional and experienced investors.
Prematurity is a problem that affects the entire society. We therefore welcome every new investor, large and small, to join our mission. Besides the powerful business case and the associated rewards, it is vital that the challenges of premature birth receive awareness in today’s private and work environments.
(You can find more information about OxyPrem also on our company website oxyprem.com).
Investing in OxyPrem supports significant advancements in neonatal care. OxyPrem's brain oxygen monitoring systems for preterm neonates help medical teams to react in time to avoid disabilities and other life-long consequences, based on a technology that has shown to reduce false positives and negatives from 17% to just 0.5%. This system is backed by strong scientific evidence, including 13 clinical trials and 17 publications. The first-launched product OxyPrem 1.4 has been used clinically on over 300 preterm patients across 38 neonatal intensive care units (NICUs) in Europe and India, receiving positive testimonials from physicians and NICU heads.
With 1 in 10 births being pre-term, the need for reliable neonatal care is substantial. Existing NIRS systems often lack the necessary precision and accuracy, creating a significant unmet need that OxyPrem's sensors effectively address. Based on a well-established technology, the marked improvement in sensitivity and performance provides substantial clinical value.
Experts view OxyPrem's business plan as solid and low-risk, offering steady, recurring income. The target market is large enough to ensure profitability, despite the typically modest earnings from medical devices. The team's extensive business experience and robust intellectual property (IP) protection, extending beyond 2038 with eight pending patents, further strengthen the company's position. Additionally, there is potential to extend NOAH's applications to monitor other parameters and to the adult market.
While OxyPrem's regulatory strategy for the second product is well-designed, unforeseen challenges could arise, potentially delaying market entry.
As a medical device company, OxyPrem must demonstrate strong market demand for its products to secure a merger or acquisition with a larger corporation.
Already have an account? Please login here .
